At VERISTOnN Sciences, innovation begins with empathy and ends with impact. Our commitment to redefining healthcare extends beyond molecules — it lies in how we deliver them more efficiently, safely, and intuitively to those who need them most.
Through our suite of proprietary delivery technologies — C3 Cura™, ORAMELT™, En-Infi™, and VesiFuze™ — we are transforming the way therapies are absorbed, experienced, and sustained. Each platform is born from a singular philosophy: to combine scientific precision with human understanding, ensuring that complex formulations translate into simpler, smarter, and more effective patient outcomes.
From oral melts that dissolve in seconds to nanocarriers that optimize bioavailability at the cellular level, from enhanced absorption systems to deep-penetrating emulgels — our technologies bridge the gap between innovation and accessibility, empowering clinicians and patients alike with breakthroughs that feel effortless yet deliver exceptional results.
Because at VERISTOnN, we don’t just develop better formulations — we design better experiences of healing.
C3 Cura™ is a proprietary bioavailability enhancement platform that revolutionizes how active pharmaceutical ingredients are absorbed and utilized by the body. It is specifically engineered to address one of the most persistent challenges in formulation science — the poor solubility of many promising molecules that limits their therapeutic potential.
Through advanced molecular engineering and solvent-free dispersion processes, C3 Cura™ converts poorly soluble or lipophilic molecules into 100% water-soluble formulations, ensuring that a greater proportion of the active ingredient is effectively delivered into systemic circulation. This results in up to 500 times higher bioavailability, enabling significant dose reduction — often as much as 99% compared to conventional formulations.
Beyond improved absorption, C3 Cura™ also enhances pharmacokinetic stability, ensuring more consistent plasma concentration and prolonged therapeutic effect. The platform reduces the metabolic burden on the liver and minimizes drug degradation, leading to lower toxicity, fewer side effects, and better patient tolerance.
Clinically, this means smaller doses can achieve the same or greater efficacy, improving adherence, convenience, and overall treatment safety — particularly for vulnerable populations such as the elderly, children, or those on multiple therapies.
In essence, C3 Cura™ is more than an absorption enhancer — it is a transformative technology redefining formulation design, enabling new product pipelines, and opening fresh possibilities in both pharmaceutical and nutraceutical innovation.
ORAMELT™ is a next-generation oral delivery platform designed to make medication administration faster, easier, and more patient-friendly — especially for those who struggle with swallowing traditional tablets or capsules.
Developed through advanced formulation science, ORAMELT™ allows the active ingredient to dissolve in the mouth within 10–15 seconds, without the need for water. The technology employs a unique combination of taste-masking polymers, moisture-activated excipients, and controlled-release film formers, ensuring a smooth mouthfeel, pleasant taste, and rapid onset of therapeutic action.
This platform is particularly beneficial for pediatric, geriatric, and chronic care patients, as well as for individuals with dysphagia, nausea, or limited access to water — offering an effortless, on-the-go dosing experience.
Beyond convenience, ORAMELT™ enhances bioavailability by promoting pre-gastric absorption through the oral mucosa, reducing first-pass metabolism and enabling faster drug delivery into systemic circulation. The result is quicker relief, improved adherence, and superior patient satisfaction.
From pain management and neurology to nutraceutical supplementation, ORAMELT™ is redefining how patients experience oral medication — transforming therapy from a routine into a moment of ease, comfort, and confidence.
At VERISTOnN, technologies like ORAMELT™ exemplify our commitment to combining scientific innovation with human empathy — creating smarter dosage forms that put the patient first, every time.
En-Infi™ represents a breakthrough in nanotechnology-based drug and nutrient delivery, designed to overcome one of modern formulation science’s greatest limitations — the poor solubility and inconsistent absorption of lipophilic (fat-soluble) actives.
This proprietary platform uses nano-emulsification and particle-size engineering to convert traditionally unstable or low-bioavailability compounds into stable, clear, and uniformly dispersed nanoparticles. These nano-sized particles — often less than 100 nanometers — dramatically increase surface area, allowing for faster dissolution, improved permeability, and sustained release of active ingredients within the body.
The En-Infi™ system is particularly effective for bioactive compounds like Vitamin D3, Curcumin, CoQ10, and other lipophilic nutrients, ensuring consistent and superior systemic delivery. By enabling better cellular uptake and minimizing degradation during digestion, this technology ensures that more of the active ingredient actually reaches its intended biological target.
From a clinical perspective, En-Infi™ not only enhances efficacy but also supports dose optimization, improved stability, and longer shelf life, making it ideal for both pharmaceutical and nutraceutical applications.
For patients, the benefits are tangible — faster onset of action, longer-lasting results, and enhanced tolerability.
For formulators, it offers a scalable, regulatory-compliant platform that elevates therapeutic performance without compromising safety or quality.
At VERISTOnN, En-Infi™ embodies our philosophy of translating scientific complexity into simple, effective, and accessible solutions — ensuring that every innovation delivers measurable health impact where it matters most.
VesiFuze™ is a next-generation topical delivery platform that merges the advantages of lipid vesicle systems with the structural stability of hydrogel matrices to deliver actives precisely where they are needed — deep into tissues, muscles, and joints.
Unlike conventional gels or creams that act only on the skin’s surface, VesiFuze™ employs deformable lipid vesicles capable of fusing with and penetrating through the stratum corneum, the skin’s toughest barrier. Once inside, these vesicles release active molecules in a controlled, sustained manner, ensuring deeper penetration, prolonged action, and enhanced therapeutic efficacy.
The emulgel base of VesiFuze™ provides excellent spreadability and stability, while the lipid component ensures optimal compatibility with both hydrophilic and lipophilic actives. This unique combination makes it ideal for the topical delivery of agents used in pain relief, inflammation control, dermatological therapy, and musculoskeletal disorders.
In practical terms, VesiFuze™ formulations offer rapid absorption, minimal greasiness, and superior patient comfort, while delivering faster relief and longer-lasting results. The vesicular fusion process also contributes to reduced systemic exposure, lowering the risk of side effects commonly seen with oral pain or anti-inflammatory medications.
Through VesiFuze™, VERISTOnN has redefined topical therapy — transforming simple applications into scientifically engineered experiences that combine efficacy, safety, and sensorial appeal. It reflects our unwavering commitment to making advanced science intuitive and accessible, improving not just outcomes, but the entire healing experience.
Sagittis eu volutpat odio facilisis mauris sit amet massa vitae. Pellentesque habitant morbi tristique senectus. Quis commodo odio aenean sed adipiscing diam donec adipiscing tristique. Eget nunc lobortis mattis aliquam faucibus purus in. Curabitur vitae nunc sed velit dignissim sodales ut eu sem.